koichi watashi - Infectious Diseases

Author Information

Koichi Watashi is affiliated with the Department of Virology II at the National Institute of Infectious Diseases, located in Tokyo, Japan. His research primarily focuses on virology and infectious diseases, contributing significantly to the scientific understanding and combat of viral infections.

Research Contributions

Koichi Watashi has made substantial contributions to the field of virology, particularly in understanding and developing treatments for viral infections such as hepatitis B, hepatitis C, and SARS-CoV-2. In 2022 alone, he co-authored several papers including research on neutralizing antibodies against SARS-CoV-2, the antiviral activity of ciclesonide derivatives, and the inhibition pathways for hepatitis B and D viruses. His work is pivotal in identifying potential therapeutic agents and vaccines targeting these viruses.

Aliases

Koichi Watashi is also referenced simply as Koichi Watashi in various publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	8594
H-index	42
Paper Count	227

Publications:

Asymmetric total synthesis of four bioactive lignans using donor–acceptor cyclopropanes and bioassay of (−)- and (+)-niranthin against hepatitis B and influenza viruses

DOI: 10.1039/d2ra00499b

Year: 2022

Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses

DOI: 10.3390/v14040764

Year: 2022

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

DOI: 10.1101/2022.02.27.482147

Year: 2022

Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine.

DOI: 10.1016/j.antiviral.2022.105266

Year: 2022

Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication

DOI: 10.1016/j.jphs.2022.04.001

Year: 2022

Determining the absolute configuration of vanitaracin A, an anti-hepatitis B virus agent

DOI: 10.1038/s41429-021-00496-1

Year: 2022

Galectin-9 restricts hepatitis B virus replication via p62/SQSTM1-mediated selective autophagy of viral core proteins

DOI: 10.1038/s41467-022-28171-5

Year: 2022

An ACAT inhibitor regulates SARS-CoV-2 replication and antiviral T cell activity

DOI: 10.1101/2022.04.12.487988

Year: 2022

Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro

DOI: 10.1101/2021.01.31.429001

Year: 2021

Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2

DOI: 10.33774/chemrxiv-2021-mcf3k

Year: 2021

What are the Key Components of HTS?

Why is Prenatal Screening Important?

How Effective Are Masks?

Why is a Malaria Vaccine Important?

How can Plasmodium falciparum malaria be prevented?

What Are the Risks Associated with Throat Swabs?

What is the Treatment for Rabies?

What is Prevalence?

How does Dengvaxia work?

What are the best practices for insect bite prevention?

Partnered Content Networks

Relevant Topics